LiveSpo NAVAX

The 3 mechanisms of action of LiveSpo Navax in supporting the treatment of respiratory diseases caused by viral and bacterial infections are as follows:

• Competition for the substances living environment and synthesis of antibacterial agents to help destroy harmful bacteria.
• Adsorption of probiotic spores, capturing viruses. (For example, 1 Bacillus subtilis spore can capture 8 H5N1 viruses.)
• Enhancement of mucosal immunity and modulation of the inflammatory response.

Until now, probiotics for the respiratory system have typically been in the form of oral supplements. However, oral intake often takes a longer time to show effects (3 – 6 months) and primarily enhances overall immune function, indirectly benefiting the respiratory system. In contrast, LiveSpo Navax is a nasal spray that delivers probiotic spores directly to the nose and throat, allowing for rapid and direct effectiveness in inflamed areas. It works through a mechanism of direct competition, capturing and inactivating bacteria and viruses that cause nasal infections (1 Bacillus spore can inactivate 8 H5N1 viruses). Additionally, it regulates cytokines and strengthens the immune system of the respiratory tract.

The Bacillus spores are purified and formulated as pre-activated spores which can adsorb viruses and competitively inhibit harmful bacteria. The pre-activated spores expedite germination, enhance biofilm formation, and facilitate the regeneration and recovery of the nasal mucosa.

LiveSpo Navax has the ability to non-specifically adsorb viruses, which means that in addition to RSV and the flu, it can also adsorb other viruses such as Coronaviruses, Adenoviruses, and more. Furthermore, research conducted at the Vietnam National Children’s Hospital has shown that LiveSpo has the ability to eliminate bacterial co-infections in the nasal tract, such as Streptococcus pneumoniae and Haemophilus influenzae.

No, oral probiotics have indirect and slow effects, which are suitable only for the prevention of respiratory infections. On the other hand, nasal-spraying LiveSpo Navax provides much quicker and more significant efficacy, making it suitable for both supportive treatment and prevention of respiratory infections.

Absolutely, and it is highly recommended. Combining LiveSpo Navax not only helps to supplement the respiratory tract with beneficial bacteria but also enhances the effectiveness of symptom treatment (10-60%) in clinical trials. In patients undergoing routine antibiotic treatment for bacterial co-infection, the additional use of LiveSpo Navax proves to be significantly more effective in inhibiting co-infecting bacteria in the nasal tract compared to the additional use of physiological saline. This is evidenced by 9 out of 10 patients in the Navax group testing negative for co-infection on day 3 of treatment, whereas only 3 out of 10 patients in the Control group achieved the same outcome.

Both products can be used daily for prevention purposes. For saving money, one can choose LiveSpo Navax Kids, which has lower Bacillus spore concentration and is cheaper, on a daily basis. LiveSpo Navax Kids contains only spores in 0.9% physiological saline, making it very safe for daily use to directly strengthen the immune system of the respiratory tract, thereby preventing respiratory diseases, especially during the changing seasons.

• LiveSpo Navax (Red-color; 30 billion spores in 30 mL/bottle): a bottle contains 140 sprays. For treatment purposes (4-6 sprays/nostril, 3-4 times/day), it can last for approximately 7 days.
• LiveSpo Navax Kid (Yellow-color; 30 billion spores in 50 mL/bottle): a bottle contains 240 sprays. For preventive purposes (2-4 sprays/nostril, 1-2 times/day), it can last for about 35-50 days.

• For otitis externa: It can be sprayed directly into the outer ear after cleaning.
• For otitis media: It is recommended to spray through the nose, taking a deep breath to ensure better access to the sinuses. Currently, LiveSpo Navax is being tested on patients with sinusitis and otitis media at Thai Binh Medical and Pharmacy Hospital, showing initial positive results. The clinical trial has been registered on ClinicalTrials.gov, NIH US, (2023): https://clinicaltrials.gov/ct2/show/NCT05804123.

Until now, LiveSpo Navax has undergone clinical trials on children infected with RSV and influenza viruses at the Vietnam National Children’s Hospital, with 8 published scientific studies. The best paper “Nasal-spraying Bacillus spores as an effective symptomatic treatment for children with acute respiratory syncytial virus infection” has been published in Nature-Scientific Reports. https://www.nature.com/articles/s41598-022-16136-z.